Total Funding
2
57
Total FundingSeries A raised
Growth Score
0 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
445511
Satiogen Pharmaceuticals is a specialty pharma company focused on novel-target for treating type 2 diabetes.
Andrew Young: Co-Founder
Slava Gedulin: Co-Founder, Vice President Research and DevelopmentPast Role: Lumena Pharmaceuticals, Co-Founder & CTO
About the Company
Satiogen Pharmaceuticals is a specialty pharma company focused on novel-target for treating type 2 diabetes. The company's metabolic mechanism therapy offers designed to regulate nutrient intake and postprandial glucose. The company's products include a substitute for metformin in gliptin formulations and an OTC nutraceutical that would
reduce body weight and postprandial glucose, enabling doctors to treat type 2 diabetes and obesity without intervention.
Women Founded
